Want to see HK:1541 full AI Analyst Report?
Top Page
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
(1541)
Select Model
Select Model
Rating:47Neutral
Price Target:
HK$3.50
▼(-43.09% Downside)
Action:Reiterated
Date:08/27/26
The score is held down primarily by weak financial performance—large ongoing losses and sustained cash burn despite strong revenue growth. Technical signals are moderately supportive in the short term, but longer-term trend indicators remain weak. Valuation is constrained by negative earnings and no dividend support.
Positive Factors
Strong revenue growth
Rapid revenue expansion indicates increasing commercial traction for the company’s oncology-focused portfolio. If growth continues, a larger revenue base can improve operating leverage, support investment in clinical development, and strengthen the potential for future profitability.
Negative Factors
Persistent deep losses
Materially negative EBIT and net income show that revenue growth has not yet translated into a sustainable earnings model. Continued losses can consume equity, constrain internal investment capacity, and leave profitability dependent on significant future operating improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
Rapid revenue expansion indicates increasing commercial traction for the company’s oncology-focused portfolio. If growth continues, a larger revenue base can improve operating leverage, support investment in clinical development, and strengthen the potential for future profitability.
Read all positive factors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (1541) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.93B
Dividend YieldN/A
Average Volume (3M)742.88K
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue Growth28.93%
EPS Growth27.27%
CountryHK
Employees202
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.53
Shares Outstanding420,477,300
10 Day Avg. Volume827,380
30 Day Avg. Volume742,882
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.73
Price to Sales (P/S)14.37
P/FCF Ratio-10.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.28Price Target Upside2.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.84
Revenue Forecast (FY)HK$122.00M
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Business Overview & Revenue Model
Company Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently und...
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 151.57M | 150.30M | 74.15M | 386.00K | 5.69M | 13.81M |
| Gross Profit | 143.34M | 134.99M | 74.15M | 7.70M | 5.69M | 13.81M |
| EBITDA | -194.09M | -203.03M | -295.63M | -355.35M | -384.49M | -718.88M |
| Net Income | -229.08M | -212.92M | -315.86M | -379.46M | -402.89M | -732.95M |
Balance Sheet | ||||||
| Total Assets | 1.03B | 1.10B | 922.00M | 874.59M | 839.98M | 892.84M |
| Cash, Cash Equivalents and Short-Term Investments | 946.44M | 1.02B | 752.12M | 608.56M | 635.21M | 668.33M |
| Total Debt | 363.12M | 228.12M | 136.36M | 74.77M | 14.62M | 18.54M |
| Total Liabilities | 406.92M | 308.40M | 243.69M | 126.30M | 60.76M | 2.49B |
| Stockholders Equity | 625.83M | 791.78M | 678.90M | 748.29M | 779.22M | -1.60B |
Cash Flow | ||||||
| Free Cash Flow | -73.16M | -197.13M | -138.44M | -370.25M | -261.93M | -315.79M |
| Operating Cash Flow | -72.41M | -195.85M | -128.03M | -367.55M | -238.71M | -190.54M |
| Investing Cash Flow | -37.19M | 2.82M | 37.95M | -294.85M | 49.00K | -108.72M |
| Financing Cash Flow | 383.00M | 397.11M | 258.93M | 331.04M | 179.38M | 793.03M |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Technical Analysis
Negative
6.15
Price Trends
3.46
Positive
3.71
Negative
4.60
Negative
Market Momentum
0.03
Positive
48.99
Neutral
18.12
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1541, the sentiment is Negative. The current price of 6.15 is above the 20-day moving average (MA) of 3.60, above the 50-day MA of 3.46, and above the 200-day MA of 4.60, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 48.99 is Neutral, neither overbought nor oversold. The STOCH value of 18.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1541.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | HK$4.82B | 8.07 | 47.76% | ― | 286.20% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$2.22B | 36.89 | 6.51% | ― | 605.95% | ― | |
47 Neutral | HK$2.93B | -5.49 | -32.32% | ― | 28.93% | 27.27% | |
47 Neutral | HK$9.72B | -19.53 | -43.54% | ― | 116.67% | -0.42% | |
46 Neutral | HK$8.10B | -42.05 | -10.27% | ― | -31.77% | -177.01% | |
44 Neutral | HK$7.96B | -71.58 | -9.49% | ― | 68.12% | 81.84% |
* Healthcare Sector Average
HK:1541
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
3.40
-11.08
-76.52%
HK:6996
Antengene Corporation Limited
3.45
-4.28
-55.37%
HK:9966
Alphamab Oncology
8.45
-2.41
-22.19%
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
6.13
-4.72
-43.50%
HK:2171
CARsgen Therapeutics Holdings Ltd.
13.43
-7.31
-35.25%
HK:2616
CStone Pharmaceuticals
6.17
-5.64
-47.75%
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Corporate Events
ImmuneOnco reshapes board with resignation and proposed appointment of independent director
Aug 28, 2026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc announced the resignation of independent non-executive director Dr. Zhenping Zhu, who is stepping down to focus on other business commitments but will remain in his role until a replacement is approved ...
ImmuneOnco Starts Phase II Trial of Dual-Immunotherapy Combo for Advanced Liver Cancer
Aug 27, 2026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has initiated a Phase II clinical trial after successfully dosing the first patient with its combination of IMM2510 (palverafusp alfa) and IMM27M (tazlestobart) for first-line treatment of advanced hep...
ImmuneOnco Advances Lead Leukemia Drug to Fully Enrolled Phase III Trial
Aug 26, 2026
ImmuneOnco reported that it continued to rapidly advance its drug pipeline in the first half of 2026, with notable milestones across both immuno-oncology and emerging non-oncology areas. The company’s dual focus aims to broaden the therapeut...
ImmuneOnco Advances PAH Candidate IMC-003 With First Patient Dosed and Phase I Enrolment Completed
Aug 25, 2026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., through its subsidiary ImmuneCare, is developing IMC-003, an activin receptor type IIA-Fc fusion protein targeting pulmonary arterial hypertension by modulating underlying vascular disease mechanisms....
ImmuneOnco Wins FDA Nod to Test Bispecific IMM0306 in Lupus Trial
Aug 21, 2026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has secured approval from the U.S. Food and Drug Administration for an Investigational New Drug application covering IMM0306 in a Phase Ib/II clinical trial for systemic lupus erythematosus. The progra...
ImmuneOnco Sets August Board Meeting to Approve Interim Results and Mull Dividend
Aug 14, 2026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a Hong Kong-listed PRC joint stock biopharmaceutical company in the immuno-oncology space, develops cancer therapies and related pharmaceutical technologies for China and global markets. The firm is l...
ImmuneOnco Boosts Metabolic and Rare Disease Subsidiary with RMB50 Million Capital Injection
Aug 6, 2026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has entered into a capital increase agreement for its non-wholly owned subsidiary, ImmuneCare Biopharmaceutical (Shanghai) Co., Ltd., which focuses on innovative drugs for metabolic and rare diseases. ...
ImmuneOnco Details ESOP-Linked Capital Increase at Non-Oncology Subsidiary
Jul 31, 2026
ImmuneOnco Biopharmaceuticals has provided further details on a capital increase at a non-oncology subsidiary that houses early-stage RD programs in metabolic and rare diseases, along with associated intellectual property and drug ownership rights...
ImmuneOnco Starts Phase II/III Trial of First-in-Class IMM0306 for IgG4-Related Disease
Jul 10, 2026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has initiated a key Phase II/III clinical trial by dosing the first patient with IMM0306 for IgG4-related disease, a chronic fibro-inflammatory disorder that can affect multiple organs and lead to orga...
ImmuneOnco flagged by HKEX over shareholder loan compliance
Jul 2, 2026
ImmuneOnco Biopharmaceuticals has disclosed that the Hong Kong Stock Exchange has ruled a shareholder loan to Dr. Tian, secured by 6,000,000 escrowed shares, is not on normal commercial terms and must comply with full connected‑transaction r...
ImmuneOnco Dilutes Stake in Subsidiary via De Minimis Connected Capital Injection
Jun 18, 2026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has entered into a capital increase agreement under which Jiaxing Changxin will inject RMB325,000 into a non-wholly owned subsidiary, referred to as the Target Company, in exchange for new registered c...
ImmuneOnco Deploys HK$87.5 Million Into Vital Ventures Cash Management Funds
Jun 17, 2026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has agreed to subscribe for HK$87.5 million of New Horizon cash management funds issued by Vital Ventures, using the group’s internal surplus cash reserves to optimize treasury management. The pr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.